Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Disorder Treatment

NCT07197801 | Recruiting

• 1 other identifier: R33DA059880-02
• Study Type: interventional
• Target: 218
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn if receiving peer recovery support (support services provided by trained "peers" with lived experience of addiction and recovery) improves retention in medication treatment among people with opioid use disorder. The main question it aims to answer is: does peer recovery support improve retention in medication treatment for opioid use disorder? Researchers will compare two groups: (1) standard care combined with a peer recovery support program, and (2) standard care alone, to see if peer recovery support works to improve retention in medication treatment for opioid use disorder. Participants will: visit clinics as they normally would to receive standard care (medication treatment for opioid use disorder); complete two questionnaires - one when they start treatment and one 6 months later; and agree to let researchers use information from their medical record. Participants in group 1 will also be invited to meet with a peer recovery support specialist for up to 6 months.

Conditions

Opioid Use Disorder

Keywords

Medication for opioid use disorder; Peer recovery support

Outcome Measures

Primary Outcomes (2)

• 6-month treatment retention

  Data will come from the electronic health records. Retention will be defined as a participant not having a lapse in days' supply of medication for opioid use disorder treatment (buprenorphine, buprenorphine-naloxone, or naltrexone) within the 6-month follow-up period that is greater than 30 days.

  180 days from initiation of medication treatment for opioid use disorder

• Length of time in treatment

  Data will come from the electronic health records. Length of time in treatment will be determined by summing days' supply of consecutive orders for medications for opioid use disorder treatment(buprenorphine, buprenorphine- naloxone, or naltrexone). Treatment will be considered ended if a participant has a gap in supply of more than 30 days.

  180 days from initiation of medication treatment for opioid use disorder

Study Arms (2)

Standard Care

NO INTERVENTION

Study participants will receive the standard care - medication treatment for opioid use disorder

Standard Care + Peer Recovery Support

EXPERIMENTAL

In addition to standard care (medication treatment for opioid use disorder), study participants will receive support provided by a peer recovery support specialist

Behavioral: Peer recovery support to enhance patient engagement in medication for opioid use disorder treatment

Interventions

Peer recovery support to enhance patient engagement in medication for opioid use disorder treatment BEHAVIORAL

The intervention adds a peer recovery support (PRS) program to standard outpatient medication for opioid use disorder treatment and medical care. The PRS program will entail meeting one-on-one with a peer recovery specialist over a 6-month period, who will utilize their lived experience with substance use and recovery to provide emotional, informational, instrumental, and affiliational support to participants.

Standard Care + Peer Recovery Support

Eligibility Criteria

• Age: 18 Years - 89 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult ≥ 18 years of age
• Initiated medication for opioid use disorder treatment in past 45 days in a Geisinger outpatient clinic
• Willing and able to give informed consent

You may not qualify if:

• Received medication for opioid use disorder treatment at a Geisinger outpatient clinic in the 90-day period prior to the treatment initiation date
• Not proficient in English

Sponsors & Collaborators

• Geisinger Clinic: lead
• UConn Health: collaborator

Study Sites (1)

Geisinger Clinic

Danville, Pennsylvania, 17822, United States

RECRUITING

MeSH Terms

Conditions

Opioid-Related Disorders

Interventions

Dosage Forms

Condition Hierarchy (Ancestors)

Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Pharmaceutical Preparations; Technology, Pharmaceutical; Investigative Techniques

Study Officials

• Melissa Poulsen, PhD

  Geisinger Clinic

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Project Manager

CONTACT

1-866-910-6486, Option 3; PEERS@geisinger.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: September 26, 2025
• First Posted: September 29, 2025
• Study Start: December 23, 2025
• Primary Completion (Estimated): January 31, 2029
• Study Completion (Estimated): July 31, 2029
• Last Updated: February 18, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF
• Time Frame: Data will be released when study results are published, or at the end of the granting period, whichever comes first. Data will be permanently archived.
• Access Criteria: De-identified datasets and meta-data will be available to access via the National Addiction \& HIV Data Archive Program (NAHDAP) repository. Accessing data will require user registration and agreement to the data repository's terms of use, which require users to make no attempt to identify human subjects, cite the data/DOI, and not redistribute the data without NAHDAP written permission.

Locations

US (1)